TAGE (toxic AGEs) hypothesis in various chronic diseases

Medical Hypotheses

Volumn 63, Issue 3, 2004, Pages 449-452

  Takeuchi, M ^a   Yamagishi, S ^b  

^a HOKURIKU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ACYLGLYCEROL; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT ANTIBODY; ALDEHYDE DERIVATIVE; ANTIBODY; EPITOPE; GLYCOLALDEHYDE; N CARBOXYMETHYLLYSINE; PENTOSIDINE; PEPTIDE; PROTEIN; PYRRALINE; UNCLASSIFIED DRUG;

AGING; ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL WALL; BRAIN; BRAIN CELL; CELL; CELL DEATH; CHRONIC DISEASE; CIRCULATION; CYTOTOXICITY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE EXPRESSION; GENETIC ANALYSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPOTHESIS; IMMUNOCHEMISTRY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MESANGIUM CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; SCHWANN CELL; SERUM; STRUCTURE ANALYSIS; TOXICITY; VASCULAR DISEASE;

AGING; ALCOHOLISM; ALDEHYDES; ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CLINICAL TRIALS; DIABETIC ANGIOPATHIES; GLYCERALDEHYDE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES;

EID: 3342891410     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.042     Document Type: Article

References (19)

1. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun. 290:2002;973-978
2. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16:2002;1928-1930
3. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6:2000;114-125
4. Takeuchi M., Yanase Y., Matsuura N., et al. Immunological detection of a novel advanced glycation end-product. Mol. Med. 7:2001;783-791
5. Koga K., Yamagishi S., Okamoto T., et al. Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int. J. Clin. Pharm. Res. 22:2002;23-27
6. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells. J. Biol. Chem. 277:2002;20309-20315
7. Nakamura S., Makita Z., Ishikawa S., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 46:1997;895-899
8. Tsuchida K., Makita Z., Yamagishi S., et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42:1999;579-588
9. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney. Int. 63:2003;464-473
10. Wada R., Nishizawa Y., Yagihashi N., et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur. J. Clin. Invest. 31:2001;513-520
11. Sasaki N., Toki S., Choei H., et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888:2001;256-262
12. Takeuchi M., Makita Z., Yanagisawa K., Kameda Y., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5:1999;393-405
13. Takeuchi M., Makita Z. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr. Mol. Med. 1:2001;305-315
14. Takeuchi M., Bucala R., Suzuki T., et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59:2000;1094-1105
15. Takeuchi M., Kikuchi S., Sasaki N., et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res. 1:2004;39-46
16. Abe R., Shimizu T., Sugawara H., et al. Regulation of human malignant melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol. 122:2004;461-467
17. Yonekura H., Yamamoto Y., Sakurai S., et al. RAGE engagement and vascular cell derangement by short chain sugar-derived advanced glycation end products. International Congress Series. vol. 1245:2002;129-135 Elsevier, Amsterdam
18. Al-Abed Y., Mitsuhashi T., Li H., et al. Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. Proc. Natl. Acad. Sci. USA. 96:1999;2385-2390
19. Takeuchi M., Watai T., Sasaki N., et al. Neurotoxicity of acetaldehyde-derived advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 62:2003;486-496